There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Julie Oomens |
| Institution: | Maastricht University |
| Department: | Psychiatry & Neuropsychology |
| Country: | |
| Proposed Analysis: | Approach This study will be performed in the context of the Amyloid Biomarker Study, a data pooling initiative aiming to harmonize and pool data from ongoing studies that have information on PET or CSF amyloid markers. We would hereby like to request ADNI data to be included as part of the Amyloid Biomarker Study (with appropriate acknowledgement in the form of co-authorships) to answer the research question specified below [1,2]. Specific Aims - To investigate whether certain protein signatures are associated with resilience to Alzheimer’s Disease (AD) pathophysiology. Design and analysis Design: Data pooling initiative. We have selected previous and ongoing studies that have information on PET or CSF amyloid markers in persons without dementia or different dementia subtypes. Data from these studies are requested, harmonized and pooled by us using established protocols. Our current dataset includes n = 12527 participants with NC, n = 1883 participants with SCI, n = 6269 participants with MCI and n = 3968 participants with dementia. In-and exclusion criteria: Studies will be included if amyloid biomarker data for participants with NC, SCD, MCI, or dementia (any type) is available. Studies focusing on other neurological, psychiatric, or other diseases that might affect the central nervous system will be excluded. Variables of interest: • Setting, way of recruitment, inclusion/exclusion criteria, cognitive status • Demographics, APOE genotype; • CSF Aβ1-42 level, t-tau level, p-tau level, CSF characteristics, amyloid-PET, amyloid-PET characteristics; • CSF proteomics data. Analyses: We will use ANCOVA to evaluate whether there are differences between protein signatures of non-resilient and resilient participants (CN participants with amyloid pathology).We will evaluate whether this association is dependent on age, gender, sex, ApoE genotype, and cognitive status. IRB comments All individual sites contributing to the Amyloid Biomarker study have obtained IRB approval. References cited [1] Jansen, WJ., Ossenkoppele, R., Knol, DL., et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. May 19 2015; 313 (19): 1924-1938. [2] Ossenkoppele, R., Jansen, WJ., Rabinovici, GD., et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. May 19 2015; 313 (19): 1939-1949. |
| Additional Investigators |
